Antidepressant treatment with fluoxetine during pregnancy and lactation modulates the gut microbiome and metabolome in a rat model relevant to depression by Ramsteijn, Anouschka S. et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=kgmi20
Gut Microbes
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/kgmi20
Antidepressant treatment with fluoxetine during
pregnancy and lactation modulates the gut
microbiome and metabolome in a rat model
relevant to depression
Anouschka S Ramsteijn , Eldin Jašarević , Danielle J Houwing , Tracy L Bale &
Jocelien DA Olivier
To cite this article: Anouschka S Ramsteijn , Eldin Jašarević , Danielle J Houwing , Tracy L
Bale & Jocelien DA Olivier (2020) Antidepressant treatment with fluoxetine during pregnancy and
lactation modulates the gut microbiome and metabolome in a rat model relevant to depression, Gut
Microbes, 11:4, 735-753, DOI: 10.1080/19490976.2019.1705728
To link to this article:  https://doi.org/10.1080/19490976.2019.1705728
© 2020 The Author(s). Published with
license by Taylor & Francis Group, LLC.
View supplementary material 
Published online: 23 Jan 2020. Submit your article to this journal 
Article views: 2898 View related articles 
View Crossmark data Citing articles: 3 View citing articles 
RESEARCH PAPER
Antidepressant treatment with fluoxetine during pregnancy and lactation
modulates the gut microbiome and metabolome in a rat model relevant to
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Anouschka S Ramsteijn a,b,c, Eldin Jašarevićb,c,d, Danielle J Houwing a, Tracy L Baleb,c,d,
and Jocelien DA Oliviera
aDepartment of Neurobiology, Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands;
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ABSTRACT
Up to 10% of women use selective serotonin reuptake inhibitor (SSRI) antidepressants during
pregnancy and postpartum. Recent evidence suggests that SSRIs are capable of altering the gut
microbiota. However, the interaction between maternal depression and SSRI use on bacterial
community composition and the availability of microbiota-derived metabolites during pregnancy
and lactation is not clear.
We studied this using a rat model relevant to depression, where adult females with a genetic
vulnerability and stressed as pups show depressive-like behaviors. Throughout pregnancy and
lactation, females received the SSRI fluoxetine or vehicle. High-resolution 16S ribosomal RNA
marker gene sequencing and targeted metabolomic analysis were used to assess the fecal
microbiome and metabolite availability, respectively.
Not surprisingly, we found that pregnancy and lactation segregate in terms of fecal micro-
biome diversity and composition, accompanied by changes in metabolite availability. However,
we also showed that fluoxetine treatment altered important features of this transition from
pregnancy to lactation most clearly in previously stressed dams, with lower fecal amino acid
concentrations. Amino acid concentrations, in turn, correlated negatively with the relative abun-
dance of bacterial taxa such as Prevotella and Bacteroides.
Our study demonstrates an important relationship between antidepressant use during the
perinatal period and maternal fecal metabolite availability in a rat model relevant to depression,
possibly through parallel changes in the gut microbiome. Since microbial metabolites contribute
to homeostasis and development, insults to the maternal microbiome by SSRIs might have health
consequences for mother and offspring.
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Dysregulation of the neurotransmitter serotonin
(also referred to as 5-hydroxytryptamine or
5-HT) in the brain is a widely recognized hallmark
of major depressive disorder.1 Selective serotonin
reuptake inhibitor (SSRI) antidepressants target
the serotonin transporter (SERT), thereby influen-
cing the serotonergic tone.2 Serotonin and SERT
are particularly well-known for playing crucial
regulatory roles in the brain, but they also act in
many peripheral tissues.3 Nearly 95% of the body’s
serotonin resides within the gastrointestinal tract,
where it is mainly produced by enterochromaffin
cells.4 Interestingly, germ-free and antibiotic-
treated mice show lower levels of colonic and
serum serotonin. This is reversible by microbial
colonization, suggesting an important role for
members of the gut microbiome in modulating
serotonin availability.5 Indeed, the gut microbiota
synthesizes tryptophan, the precursor of serotonin,
and promotes serotonin biosynthesis in the host
organism.5 Conversely, host serotonin signaling
impacts the gut microbiota composition as we
have shown in rats,6 and others in mice,7 with
reduced or no SERT gene expression.
Correspondingly, in vitro studies have shown that
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serotonin affects the growth of microbes such as
Escherichia coli and Rhodospirillum rubrum,8 and
activates bacterial quorum sensing.9 Several studies
have found alterations in the gut microbiota com-
position of patients with major depression10-16 and
rodents with depressive-like symptoms.17-21
Moreover, recent human population-based
studies,16,22,23 as well as rodent experiments,24-29
showed that SSRIs modulate the gut microbiota
composition, an effect that may be related to
their in vitro antimicrobial properties.24,30,31
The gut microbiota synthesizes a variety of meta-
bolites that reach the systemic circulation,32,33 which is
of special relevance during pregnancy and lactation
when there is a high metabolic demand.34 Indeed,
pregnancy is characterized by hormonal, immunolo-
gical andmetabolic changes, paralleled by remodeling
of thematernal gutmicrobiome.35 Environmental and
pharmacological insults disrupt the compositional
and functional states of the maternal gut microbiota,
as demonstrated by several animal studies focusing on
stress,36 diet,37 and antibiotic use during pregnancy.38
Despite clear evidence that the microbiome interacts
with serotonin homeostasis,39 it is currently unknown
how alterations in serotonin signaling affect the
maternal gut microbiome during the perinatal period.
An estimated 7 to 13% of women suffer from a major
depressive disorder in the perinatal period.40 It was
recently shown that there are associations between
anxiety and the fecal microbial composition during
pregnancy.41 Between 1 and 10% of pregnant women
take SSRI antidepressants,40 further highlighting the
relevance of a potential effect of SSRI medication
during this period on the gut microbiota and its meta-
bolic output.
We investigated the hypothesis that a depressive-
like phenotype, SSRI antidepressant treatment, and
their combination affect the microbial community
composition and function during pregnancy and
the postpartum period. To this end, we used
a genetic rat model of maternal vulnerability
(MV) in combination with early life stress (sMV)
or control handling (cMV). In adulthood,
sMV females show a depressive-like phenotype,
reflected in a lower sucrose preference and lower
neural growth factor gene expression than cMV
females.42 We treated sMV and cMV rats dams
daily with fluoxetine (FLX), a commonly used
SSRI, or vehicle (Veh) throughout pregnancy and
lactation. Weekly fecal samples were collected for
16S rRNA gene sequencing. In addition, targeted
metabolomic analysis of amino acids, short-chain
fatty acids and bile acids was done on a subset of
samples. We examined the hypothesis that depres-
sive-like symptoms and antidepressant treatment
during pregnancy and lactation affect the maternal
fecal microbiome and its functional capacity. We
expected the combination of sMV and FLX to have
the strongest effect.
Results
We examined the hypothesis that depressive-like
symptoms and antidepressant treatment with
FLX during pregnancy and lactation affect the
maternal fecal microbiome composition and
function. Maternal vulnerability (MV) rats were
used, since early life stress produces depressive-
like symptoms and shifts in fecal microbiome
community composition in these animals
(Figure 1(a)).6,42 In line with this, we observed
pre-conception differences between the stressed
(sMV) and the control (cMV) groups, with the
sMV group showing higher alpha diversity than
the cMV group (Supplementary Figure 1a, t30
= −2.0709, p < .05). This coincided with differ-
ences in Operational Taxonomic Unit (OTU)
relative abundance (Supplementary Figure 1b).
Then, throughout gestation and the postpartum
period, sMV and cMV females were treated with
FLX or Veh daily (Figure 1(b)). Weekly fecal
pellets were collected for 16S rRNA sequencing
and a subset was used for targeted metabolomic
analysis in addition to sequencing (Figure 1(b)).
Pregnancy and lactation have distinct fecal
microbial signatures
To examine whether pregnancy and lactation have
distinct fecal microbial signatures, we first analyzed
the 16S rRNA sequencing data in terms of microbial
alpha diversity and community structure over all
treatment groups. Alpha diversity was higher during
pregnancy than during lactation, as expressed in the
Shannon diversity index (Figure 2(a), t158 = 7.5845,
p < .0001). The differences in phylogenetic structure
between samples were explored by assessing
weighted UniFrac distances. A separation between
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samples obtained during pregnancy versus lactation
was revealed by Principle Coordinates Analysis
(PCoA) (Figure 2(b), PERMANOVA p = .001).
In order to identify the bacterial signatures that
underlie the observed shift in community struc-
ture between pregnancy and lactation, a machine-
learning approach called Random Forests was
used to analyze the data of the cMV-Veh group.
This generated a model containing 28 OTUs at
the genus-level, discriminating between preg-
nancy and lactation. A large reorganization of
the microbiome composition from gestation to
lactation was revealed, consistent with structural
remodeling. Particularly within the Bacteroidales
and Clostridiales orders, OTUs changed in their
relative abundance from pregnancy to lactation
(Supplementary Figure 2a).
Fluoxetine treatment alters the maternal fecal
microbial signatures of pregnancy and lactation
in a rat model for depressive-like behavior
To test whether early life stress, FLX, and their
combination alter the observed fecal microbial sig-
natures of pregnancy and lactation, we first com-
pared the groups with respect to alpha- and beta
diversity measures. During pregnancy, we found
a main effect of early life stress on microbial alpha
diversity, with the sMV groups showing a higher
Shannon diversity index than the cMV groups
(Figure 2(a), F1,60 = 4.690, p < .05). Post hoc analysis
revealed no significant differences between groups.
During lactation, there was a significant FLX * early
life stress interaction effect (Figure 2(a), F1,92 = 5.256,
p < .05) and a trend toward a main effect of stress
Figure 1. Overview of study design and sampling schedule. (a) Early life stress protocol. SERT+/- females were crossed with SERT+/-
males, yielding nests with offspring genotypes SERT+/+, SERT+/-, and SERT−/-. The SERT+/- females are our model of maternal
vulnerability (MV). From postnatal day (PND) 2 to PND15, pups were either maternally separated for 6 hours per day (early life
stress – sMV) or control handled (cMV) for 15 minutes per day. Pups were weaned at PND21. sMV- and cMV females were group
housed (same treatment) until adulthood. (b) Fluoxetine treatment during pregnancy and lactation, and fecal sampling schedule.
Adult sMV and cMV females (N = 14–18/group) were crossed with wildtype males. Throughout pregnancy and lactation, from
gestational day (GD)1 until PND21, females received a daily oral injection of either 10 mg/kg fluoxetine (FLX) or methylcellulose
(Veh). Thus, there were 4 groups of females: cMV-Veh, sMV-Veh, cMV-FLX, and sMV-FLX (N = 6–11/group). Fecal pellets for 16S rRNA
gene sequencing were freshly collected before conception at GD0, during pregnancy at GD7 and GD14, at PND2, and during
lactation at PND7, PND14 and PND21 (N = 192 in total). Selected fecal samples from GD7 and PND7 were also used for metabolomic
analysis (N = 4-5/group per time point, N = 36 in total).
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Figure 2. Fluoxetine treatment alters the microbiome during pregnancy and lactation in rats with a depressive-like phenotype. (a)
Microbial alpha diversity. A t-test was performed to assess the overall difference between pregnancy and lactation. Within each
period, a two-way ANOVA was performed. (b) Structure of the microbial communities during pregnancy and lactation. Communities
were clustered using PCoA of the weighted UniFrac distance matrix. Each point corresponds to the microbial community of one
sample. The percentage of variation explained by the PC is indicated on the axes. Colors correspond to period; all samples were
grouped within pregnancy and lactation. (c) The effect of FLX on the structure of the sMV microbiome during pregnancy and
lactation. Each point corresponds to the microbial community of one sample that was collected during pregnancy (upper graph) or
lactation (lower graph). Colors correspond to group; sMV-Veh in white and sMV-FLX in gray. (d) Heatmap of relative abundances of
Random Forests-identified OTUs distinguishing between pregnancy and lactation, ordered by unsupervised clustering. (e) Relative
abundance of selected Random Forests-identified OTUs. Two-way ANOVAs within pregnancy and lactation were used to analyze OTU
relative abundance. Note: this analysis was performed on centered log-ratio transformed data (see Methods). N = 12–22 samples/
group from pregnancy (N = 64 in total), N = 18–33/group from lactation (N = 96 in total).
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(F1,92 = 2.784, p = .0986). Post hoc analysis revealed
that the Shannon diversity index was significantly
higher in the sMV- than in the cMV group during
lactation (p < .05). In terms of microbial community
structure, the treatment groups dissociated based on
PCoA of the weighted UniFrac distances
(Supplementary Figure 2b, PERMANOVA
p = .001). In particular, microbial community struc-
ture in the sMV-FLX group differed from the struc-
ture in the sMV-Veh group, both during pregnancy
and lactation (Figure 2(c), pregnancy sMV-Veh vs
sMV-FLX PERMANOVA p < .05, lactation sMV-
Veh vs sMV-FLX PERMANOVA p = .001). This
suggests that, in addition to the dynamic restructur-
ing of the fecal microbiome across pregnancy and
lactation, fluoxetine treatment modulated commu-
nity structure of the fecal microbiota in the sMV
females during these periods.
Next, the relative abundance of the 28 OTUs
constituting the Random Forests-generated model
discriminating between pregnancy and lactation in
the cMV-Veh group was examined for the treat-
ment groups. Globally, the pattern of OTUs dis-
tinguishing between pregnancy and lactation in
the treatment groups was similar to that of the
cMV-Veh group (Figure 2(d)). However, specific
OTUs showed variations in their relative abun-
dance dependent on treatment as tested by two-
way ANOVAs (FLX * early life stress) within
pregnancy and lactation (Figure 2(e);
Supplementary Figure 2c). For instance, the 2
OTUs with the largest contribution to the accuracy
of the Random Forests model, Bacteroides and
Prevotella from the Bacteroidales order, were sen-
sitive to FLX treatment. Bacteroides relative abun-
dance was lower in the FLX groups than in the
Veh-treated groups during pregnancy (Figure 2(e),
main effect of FLX, F1,60 = 13.206, p < .001). Post
hoc testing revealed that specifically the cMV-FLX
group had a lower relative abundance of
Bacteroides than the cMV-Veh group (p < .01).
During lactation, a trend for a FLX * early life
stress interaction was found for Bacteroides rela-
tive abundance (F1,92 = 3.774, p = .0551), with
a trend for a lower relative abundance in the sMV-
FLX group than in the sMV-Veh group
(p = .0764). The opposite effect was found for
Prevotella, with a main effect of FLX on
Prevotella relative abundance during pregnancy
(F1,60 = 16.488, p < .001). Specifically, there was
a trend for higher Prevotella relative abundance in
the cMV-FLX than in the cMV-Veh group
(p = .0944), and a statistically significant higher
Prevotella relative abundance in the sMV-FLX
group than in the sMV-Veh group (p < .01).
During lactation, a FLX * early life stress interac-
tion effect was found (F1,92 = 8.520, p < .01), as
well as a main effect of FLX (F1,92 = 4.249, p < .05).
Post hoc testing revealed a higher Prevotella rela-
tive abundance in the sMV-FLX group than in the
sMV-Veh group (p < .01) and the cMV-FLX group
(p < .05), reaching almost 25% relative abundance.
Similarly, there was a main effect of FLX during
pregnancy on Ruminococcus relative abundance
(F1,60 = 26.166, p < .0001), where both the cMV-
FLX group relative to the cMV-Veh group
(p < .05) as well as the sMV-FLX group relative
to the sMV-Veh group (p < .001) had a higher
relative abundance of Ruminococcus. During lacta-
tion, a FLX * early life stress interaction was found
(F1,92 = 4.245, p < .05), and a trend for a main
effect of FLX (F1,92 = 3.575, p = .0618). Post hoc
analysis revealed a higher Ruminococcus relative
abundance in the sMV-FLX group relative to the
sMV-Veh group (p < .05). Early life stress by itself
did not have effects as striking as FLX, although
during pregnancy relative abundance of
Adlercreutzia and UC Lachnospiraceae were higher
and Lactobacillus lower in stressed dams than in
controls (Supplementary Figure 2c).
Considering that OTUs within a community dis-
play co-occurrence and co-exclusion relationships,43
we performed a correlation analysis to look at these
relationships within our samples, regardless of time of
sampling or treatment. A correlation matrix between
the 28 selected OTUs revealed that Prevotella was
negatively correlated with a cluster consisting mainly
of Clostridiales and Desulfovibrionales
(Supplementary Figure 2d). Ruminoccus was the
exception within the Clostridiales, being positively
correlated with Prevotella.
Together, these results confirm that pregnancy
and lactation are distinct with regard to fecal
microbiota diversity and composition. Although
early life stress increased alpha diversity during
lactation, there were limited effects of early life
stress alone on either microbial community
structure or on the relative abundance of OTUs
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resulting from our Random Forests model.
However, FLX impacted community structure
during pregnancy and lactation, as well as the
relative abundance of a number of OTUs
selected for their ability to distinguish between
pregnancy and lactation. FLX in combination
with early life stress had the largest effects on
the maternal microbiome.
Pregnancy and lactation have distinct fecal
metabolic signatures
Bacterial communities metabolize and synthesize
a number of metabolites that are essential for both
dam and offspring. Shifts in bacterial community
composition and predictive function may suggest
alterations in the capacity of these communities to
synthesize or metabolize these metabolites. We first
performed PICRUSt predictive analysis on the OTU
data to explore the hypothesis that the functional
potential of pregnancy and lactation is different,
since they have different microbial signatures. To
this end, Random Forests analysis was performed
on PICRUSt-generated data from the cMV-Veh
group. Nine KEGG pathways were significantly
changed across pregnancy and lactation, including
the pathway of lysine biosynthesis; the pathway of
alanine, aspartate, and glutamate metabolism; and
the pathway of arginine and proline metabolism
(Figure 3(a); Supplementary Figure 3a). Overall,
pathways related to amino acid synthesis and meta-
bolism were among the metabolic pathways best able
to characterize the difference in the predicted func-
tion of the maternal bacterial community during
pregnancy vs lactation.
To determine whether this altered predictive meta-
bolic capacity of the microbiome was associated with
actual metabolite availability, we measured the con-
centration of amino acids, bile acids, and short-chain
fatty acids in a subset (N= 4–5 per group in pregnancy
and lactation) of fecal pellets previously used for 16S
rRNA sequencing (Supplementary Table 1).
Corresponding to the microbiome results, principle
component analysis (PCA) revealed a clear distinction
in metabolic profile between samples obtained during
pregnancy versus lactation (Figure 3(b), upper graph).
To reveal the metabolic signatures of pregnancy
and lactation, Random Forests analysis was per-
formed on the metabolite data from the cMV-Veh
group. Fourteen metabolites were included in the
resulting model to distinguish between pregnancy
and lactation (Supplementary Figure 3b). Most of
them were amino acids, and 11 out of 14 metabolites
were higher in concentration during pregnancy than
during lactation (Figure 3(c)). For instance, the
amino acids isoleucine and methionine had higher
concentrations during pregnancy than during lacta-
tion, while proline concentrations were higher dur-
ing lactation than during pregnancy (Supplementary
Figure 3c). The bile acids deoxycholic acid and taur-
ochenodeoxycholic acid were both higher in concen-
tration during pregnancy than during lactation. Of
the short-chain fatty acids included in the Random
Forests model, isocaproic acid concentrations were
very low during pregnancy, whereas isovaleric acid
concentrations were low during lactation. Overall,
the metabolomic results were consistent with the
microbiome findings and the predictive functional
analysis in discriminating between pregnancy and
lactation and pointing toward amino acids as being
central to this shift.
Fluoxetine treatment alters maternal fecal
metabolite availability during pregnancy and
lactation in a rat model for depressive-like
behavior
To investigate whether early life stress, FLX and their
combination affect the abovementioned fecal metabolic
signatures of pregnancy and lactation as observed in the
cMV-Veh group, we compared these groups with
respect to predicted- and measured metabolic data.
The effects of early life stress and FLX on the abundance
of predictive pathways were mixed, with the sMV-FLX
group having generally the lowest predicted abundance
of thesemetabolic pathways (Figure 3(a)). Visual inspec-
tion of the PCA graph based on the metabolite concen-
tration table revealed no clear effect of early life stress or
FLX treatment (Figure 3(b), lower graph).
Next, the concentrations of the 14 metabolites
included in the Random Forests-generatedmodel dis-
criminating between pregnancy and lactation in the
cMV-Veh group were examined for the treatment
groups. Similar to the microbiome results, the overall
pattern of metabolite availability changes between
pregnancy and lactation was similar in all groups
(Figure 3(c)). However, fecal amino acid
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Figure 3. Fluoxetine alters fecal metabolite availability during pregnancy and lactation in rats with a depressive-like phenotype. (a)
Heatmap of Random Forests-identified PICRUSt-generated KEGG pathways distinguishing between pregnancy and lactation, ordered
by unsupervised clustering. (b) Structure of the metabolomic composition during pregnancy and lactation. Samples were clustered
using PCA of the metabolomics concentration table. Each point corresponds to the metabolic capacity of one sample. The
percentage of variation explained by the PC is indicated on the axes. Colors correspond to period in the upper graph, and to
group in the lower graph. (c) Heatmap of Random Forests-identified metabolite concentrations distinguishing between pregnancy
and lactation. (d) Concentrations of selected amino acids, analyzed with two-way ANOVAs within pregnancy and lactation. (e)
Metabolite Set Enrichment Analysis of pregnancy vs lactation per group. Only the pathways that were significantly altered between
pregnancy and lactation are shown here; the full list of metabolic pathways is shown in Supplementary Figure 3e. For a: N = 12–22
samples/group from pregnancy (N = 64 in total), N = 18–33/group from lactation (N = 96 in total). For b-e: N = 4-5/group from
pregnancy (N = 18 in total), N = 4-5/group from lactation (N = 18 in total). Abbreviations: biosynth. = biosynthesis; degrad. =
degradation; metab. = metabolism.
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concentrations were affected by FLX treatment
(Figure 3(d), Supplementary Figure 3c). There was
a trend toward a main effects of FLX on aspartic acid
concentrations during pregnancy (F1,16 = 4.090,
p = .0602) and a significant main effect during lacta-
tion (F1,16 = 9.689, p < .01). There was also a trend
toward amain effect of early life stress on aspartic acid
concentration during lactation (F1,16 = 3.868,
p = .0668). Between-group post hoc analysis revealed
a significantly lower concentration of aspartic acid in
the sMV-FLX group relative to the sMV-Veh group
(p < .05). For serine concentrations, we found a FLX *
early life stress interaction effect during pregnancy
(F1,16 = 5.868, p < .05), as well as a main effect of FLX
(F1,16 = 25.314, p < .001). In particular, there was
a trend for lower serine concentrations in the cMV-
Veh group than in the sMV-Veh group (p = .0565),
and significantly lower concentrations of serine in the
sMV-FLX group than in the sMV-Veh group
(p < .001). For threonine concentrations, we found
a trend for a main effect of FLX during pregnancy
(F1,16 = 3.598, p = .076), where the FLX groups show
decreased threonine levels.
Since, by restricting ourselves to Random Forests-
identified metabolites, we might miss interesting
effects of our treatments on metabolites that do not
differ between pregnancy and lactation, we decided
to also analyze those metabolites as well with two-
way ANOVAs within pregnancy and lactation
(Supplementary Figure 3d). We found that FLX
was associated with lower concentrations of the
amino acid glutamic acid during lactation (F1,16
= 8.200, p < .05), and with lower levels of the bile
acids betamuricholic acid (F1,16 = 5.543, p < .05) and
omegamuricholic acid (F1,16 = 7.002, p < .05) during
pregnancy. Interestingly, within the short-chain fatty
acids, isobutyric acid concentrations were decreased
by FLX during pregnancy (trend, F1,16 = 3.952,
p = .0642) and during lactation (F1,16 = 5.902,
p < .05), while butyric acid was increased by FLX
during lactation (F1,16 = 5.019, p < .05).
Next, we used Metabolite Set Enrichment Analysis
(MSEA) to identify the fecal metabolite sets that
were enriched during either pregnancy or lactation.
In the cMV-Veh group, there were several pathways
that significantly differed between these two periods,
again containing amino acid-related pathways such
as glycine and serine metabolism (Figure 3(e);
Supplementary Figure 3e). Then, we performed
MSEA on the sMV-Veh, cMV-FLX and sMV-FLX
data to determine which metabolites involved in
specific metabolic processes were enriched in either
pregnancy or lactation. The sMV-Veh group, like the
cMV-Veh group, contained a number of metabolite
sets that distinguished between pregnancy and lacta-
tion, such as methionine metabolism, and glycine
and serine metabolism. In contrast, in the cMV-
FLX and sMV-FLX groups no metabolite sets were
identified that differed significantly between preg-
nancy and lactation. Thus, fluoxetine treatment low-
ered the fecal concentrations of several key amino
acids during the dynamic periods of pregnancy and
lactation in our model for maternal depressive-like
symptoms. In addition, fluoxetine treatment abol-
ished the differences in MSEA-identified pathways
that distinguished the fecal metabolome during preg-
nancy from lactation as observed in the Veh-treated
groups.
The relative abundances of fecal bacterial taxa
correlate with metabolite concentrations
Finally, we generated a correlation matrix to
further explore the link between the composition
of the microbiome and the availability of metabo-
lites (Figure 4). We collapsed all treatment groups
in this analysis to capture the full range of varia-
tion in both OTU abundance and metabolite con-
centrations. A cluster consisting of OTUs from the
Clostridiales (including UC Peptococcaceae,
Clostridia; other and Oscillospira) and
Desulfovibrionales (Desulfovibrio and UC
Desulfovibrionaceae) orders was positively corre-
lated with amino acid concentrations. Showing
almost the reverse pattern, the relative abundance
of Prevotella was negatively correlated with avail-
ability of isobutyric acid and a collection of amino
acids; alanine, isoleucine, glycine, methionine, and
serine. Associating to a different set of metabolites,
the relative abundance of Ruminococcus was inver-
sely correlated with concentrations of aspartic acid
and some bile acids; betamuricholic acid, omega-
muricholic acid, and alphamuricholic acid.
Overall, the OTUs that were most affected in rela-
tive abundance by FLX treatment (Bacteroides,
Prevotella and Ruminococcus) were correlated
with amino acid availability.
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Discussion
Our study shows that antidepressant treatment with
fluoxetine (FLX) during pregnancy and lactation dis-
rupts metabolite availability in a rat model for mater-
nal depressive-like symptoms, possibly through
alterations in bacterial community composition and
function. In short,maternal vulnerability (MV) female
rats were exposed to early life stress (sMV). In adult-
hood, sMV and control (cMV) females were treated
throughout gestation and lactation with the SSRI FLX
or vehicle (Veh). Fecal samples were collected for 16S
rRNA sequencing and targeted metabolomics.
We first explored the distinct fecal microbial signa-
tures of pregnancy and lactation in cMV-Veh females.
Human studies showed a remodeling of the micro-
biome from the first- to the third trimester, with
changes in diversity and composition.44 Similarly,
the maternal microbiome in mice changes from early
to late pregnancy.36 Paradoxically, here we observed
stability of the microbiome over pregnancy, poten-
tially related to the fact that we had no samples during
the first week of gestation, only starting at GD7.
Likewise, a human study in which fecal sampling did
not cover the first few weeks post-fertilization
reported stability of the microbiome over the course
of pregnancy.45 In addition, stability of the human
microbiome over lactation has been observed.46 We
complement these studies by instead defining distinct
microbial signatures associated with pregnancy versus
lactation, periods with dynamic hormonal, immuno-
logical and metabolic changes.35 Specifically, we
showed that the transition frompregnancy to lactation
in rats was characterized by a decrease in alpha diver-
sity and a large reorganization of the structure of the
fecal microbial community, with an increase in
Prevotella at the cost of Bacteroides within the
Figure 4. Correlation matrix of metabolites and OTUs throughout pregnancy and lactation. Spearman’s rank correlations were
determined between the 14 Random Forests-identified metabolites and the 28 Random Forests-identified OTUs. The circles
represent the correlation between each metabolite and OTU. The size of the circle increases with decreasing p-value-, and the
color of the circle corresponds to the ρ-value of the correlation (the strength of the correlation). Only significant (p < .05)
correlations are plotted, and only the OTUs with at least 1 significant correlation are shown here. The matrix is ordered by
hierarchical clustering. N = 4-5/group from pregnancy (N = 18 in total), N = 4-5/group from lactation (N = 18 in total).
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Bacteroidales, and an increase in Ruminococcus at the
cost of other Clostridiales OTUs.
We then hypothesized that early life stress and
FLX alter the observed fecal microbial signatures
of pregnancy and lactation. It has been shown
repeatedly that early life stress by maternal
separation in rodents produces long-term effects
on the gut and its microbiome.47-52 We showed
here that adult sMV females had a higher fecal
alpha diversity than cMV females pre-conception,
during pregnancy and during lactation. We have
previously found this tendency in young rats,6
suggesting that our stress protocol induces an
immediate and life-long increase in microbial
alpha diversity. This is surprising, since other
studies of early life stress by maternal separation
in rodents have reported a decrease in alpha
diversity,21,51 or no effect.52 In fact, a more
diverse microbiome is usually positively asso-
ciated with health.53 However, it likely depends
on the identity of the bacteria that make a more
diverse community, whether health outcomes are
positive or negative. Stressed females had
a reduced relative abundance of Lactobacillus
during pregnancy, a microbe known for its ben-
eficial health effects.14 Early life stress did not
affect the overall composition of the maternal
microbiome like it did pre-conception, possibly
due to a masking effect by pregnancy and
lactation.
Treatment with the SSRI fluoxetine, however, was
associated with major alterations in the maternal
fecal microbiome. Human population-based studies
also show that SSRI use associates with distinct char-
acteristics of the microbiome.16,22,23 Moreover,
recent experiments showed that FLX alters the gut
microbiota in rats,24,27 and in mice.25,26,28,29
Interestingly, the specific bacteria underlying this
difference do not match between studies (Table 1).
Whereas we found significant increases in Prevotella
and Ruminococcus relative abundance during preg-
nancy and lactation in FLX-treated rats, Cussotto
et al. report a complete depletion of some
Prevotella OTUs in FLX-treated male rats,24 and
Lukić et al. found many Ruminococcaceae OTUs to
be lower in FLX- and escitalopram-treated mice
relative to controls.26 Whether inconsistencies like
these are due to differences in life stage and sex –
none of the other studies was done in females in the
perinatal period – or other factors such as genetic
background remains to be investigated. In addition,
it is not clear how SSRIs might achieve their effect on
the microbiota. In vitro studies suggest that SSRIs
possess antimicrobial properties,24,30,31 possibly by
inhibiting efflux pumps or by acting on bacterial
homologs of the SERT or biogenic amine
receptors.31,54,55 Alternatively, it is possible that
SSRIs alter the intestinal habitat through their
known impact on host SERT functioning and gut
homeostasis.3 Our results here confirm that SSRIs






Cussotto et al. 201924 Male rats, 28 days of 10 mg/
kg/day, in drinking water
Alpha diversity: no significant difference Yes
OTU abundance: depletion of Prevotella 7 and 9 No; we found increases in
Prevotella
Lyte et al. 201925 Male mice, 29 days of 20 mg/
kg/day, oral gavage
Alpha diversity: no significant difference Yes
OTU abundance: decrease in S24–7 (Bacteroidales) Potentially; we found
decreases in several
Bacteroidales OTUs
Lukić et al. 201926 Male mice, 21 days of 10 mg/
kg/day, IP injections
Alpha diversity: decrease No
OTU abundance: decrease in Ruminococcus No
Zhu et al. 201927 Male rats, 21 days of 2 mg/
kg/day, oral gavage, daily
stress
Alpha diversity: no significant difference Yes
OTU abundance: Prevotellaceae Ga6A1 decreased, and




Fung et al. 201928 Male and female mice,
7 days of 10 mg/kg/day, oral
gavage
OTU abundance: decrease in Turicibacter No (data not shown)
Sun et al. 201929 Male mice, 21 days of 12 mg/
kg/day, oral gavage, daily
stress
Alpha diversity: no significant difference Yes
OTU abundance: decrease in Bacteroides Yes
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have the potential to modulate the fecal microbiome
during pregnancy and lactation in rats.
Since we have previously shown that early life
stress interacts with a reduction in serotonin trans-
porter availability to inflate its effect on the gut
microbiome composition, we expected our sMV-
FLX animals to show the largest effects.6 Indeed,
FLX significantly affected overall bacterial commu-
nity structure only in sMV females. It might be that
the sMV microbiome, belonging to a depressive-like
host, is more unstable and sensitive to disruptions
than the cMV microbiome, especially during the
dynamic perinatal period. In this proposed double-
hit model, it is the combination of early life stress
and FLX that shifts the balance in the gut microbial
community. Analogously, another study using early
life stress by maternal separation reported a change
in the gut microbiome only after a second stressor in
adulthood,56 strengthening this double-hit
hypothesis.
Next, we tested the hypothesis that the effects of
FLX on the sMVmaternal microbiome during preg-
nancy and lactation would be reflected in an altered
functional output of the microbial community. It
was shown recently that fluoxetine treatment in
rats is associated with several altered metabolic path-
ways in feces, including neurotransmitter synthesis,
fatty acid metabolism, and bile acid metabolism.57 It
is also known that gut microbes greatly affect host
plasma and fecal metabolite availability.32,33
Microbes modify and produce amino acids, bile
acids and short-chain fatty acids that become avail-
able to the host.58 Thus, we measured the concentra-
tions of these metabolites in a subset of fecal samples
that were used for microbiome analysis. Most meta-
bolites were higher in concentration during preg-
nancy than during lactation, reflecting either
greater metabolite intake or production during preg-
nancy, or more breakdown or transfer to the off-
spring during lactation. sMV-FLX animals had lower
levels of serine during pregnancy, and lower levels of
aspartic acid during lactation than sMV-Veh ani-
mals. Interestingly, amino acids that were relatively
low in FLX-treated animals, such as threonine, can
serve as precursors of microbial short-chain fatty
acid synthesis.59 We found a corresponding decrease
in isobutyric acid concentration as a result of FLX
treatment. Cussotto et al. also found a lower mean
isobutyric acid concentration in the feces of FLX-
treated animals than in controls, although this was
not a statistically significant effect.24 Overall, FLX
treatment was associated with lower fecal availability
of amino acids, most strongly in sMV females, point-
ing to a potential role for FLX in altering bacterial
nitrogen regulation.60
Finally, to link microbes to metabolites, we gen-
erated correlation matrices both within the bacterial
taxa that changed from pregnancy to lactation, as
well as between the relative abundance of these taxa
and metabolite concentrations that changed from
pregnancy to lactation. We found that the relative
abundance of Prevotella, enhanced in the sMV-FLX
group, was negatively correlated with a cluster of
Clostridiales and Desulfovibrionales genera.
Interestingly, these same Clostridiales and
Desulfovibrionales OTUs were positively associated
with availability of amino acids (with the exception
of aspartic acid). Previous literature describes that
some of the most prevalent amino acid fermenting
microbes indeed belong to the Clostridiales and
Proteobacteria taxa.61 The second highly abundant
OTU in the sMV-FLX group, Ruminococcus, was
negatively correlated to the primary (beta-
muricholic acid) and secondary (omega-muricholic
acid) bile acids that were in pregnancy in the feces of
FLX treated females, potentially mediated by
a decrease in Lactobacillus relative abundance. Bile
acids have been reported to induce serotonin release
from enterochromaffin cells,62 hinting to a potential
negative feedback mechanism. The associations we
report here yield a working hypothesis that FLX
during the perinatal period – at least in an animal
model for depressive-like behavior – tips the balance
toward higher abundance of Prevotella and
Ruminococcus and lower abundance of amino acid-
fermenting and bile acid-associated OTUs, leading
to lower fecal availability of these metabolites. Since
Prevotella and Ruminococcus are known mucin-
degraders,63 and breakdown of the protective
mucin layer of the gastrointestinal tract could have
health effects for the host, it would be interesting to
study whether mucin-degrading enzymes are
enriched in FLX-treated animals in the future.
This study has several limitations. Using the 16S
rRNA marker gene sequencing approach, our ana-
lysis was constrained to the genus level. Species
within the same genus, however, might differ in
their capacity to produce metabolites,64 which
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creates a limitation in finding and interpreting
associations between OTUs and metabolites in
this study. In addition, we are aware that the
microbiome and its functional capacity varies
across locations in the gastrointestinal tract,65
whereas we only used fecal samples. In fact, the
effect of FLX on the microbiome likely varies
along the gastrointestinal tract, since fluoxetine is
absorbed almost completely.66 However, FLX can
still be recovered from feces as was shown in
humans,67 and in this way could have an effect
even on distal portions of the gut. Lastly, since we
only measured metabolite concentrations in feces,
it is still unclear whether and how the effect of
FLX on the gut microbiome is associated with
their systemic availability.
The benefits of performing microbiome research
on laboratory rodents as opposed to humans deserve
mentioning here. For example, diet composition
could be kept stable throughout the study, whereas
diet composition changes considerably from pre-
conception to pregnancy in humans and even short-
term changes in diet are known to affect the gut
microbiome.68,69 In addition, we are able to study
the independent effect of SSRI use in rodents, as well
as its interactions with a depressive-like phenotype.40
At the moment, there is a paucity of studies into the
effect of SSRI on the microbiome from clinical stu-
dies on depression or animal studies mimicking this
condition. For instance, it is unclear whether any
effects SSRIs might have on the microbiome are
part of their therapeutic potential or should rather
be seen as side effects.70 However, the biggest asset of
the current study is our ability to link changes to the
microbiome and its predicted functional capacity to
changes in metabolite availability.
In conclusion, we showed here that fluoxetine
treatment modulated key aspects of maternal
microbial community dynamics and metabolite
output, mainly in sMV females. Our results add
to the growing body of research linking seroto-
nin signaling to the gut microbiome, as well as
to the emerging awareness that the maternal
microbiome is plastic and vulnerable to environ-
mental and pharmacological insults. Maternal
depression and SSRI use during pregnancy are
both associated with detrimental developmental
outcomes in offspring, such as lower birth
weight, delayed motor development, and
increased anxiety.71 Future studies will assess
whether and to what extent the maternal gut
microbiome and metabolome might mediate
these effects. Amino acids play essential roles
in both homeostatic physiology in adults as
well as in development and survival of the
fetus.34 Microbial molecules have been shown
to transfer from mother to offspring to support
the development of the brain and the immune
system, emphasizing their importance.72,73 If the
dampening effect of SSRI treatment on fecal
amino acid concentrations is replicable, and if
these concentrations correlate with plasma levels
and with maternal and offspring health out-
comes, modification of the maternal microbiome
(by prebiotics or probiotics) or dietary supple-
mentation of amino acids (i.e. postbiotics)




The animals came from our colony of serotonin
transporter knockout (SERT−/−, Slc6a41Hubr) Wistar
rats at the University of Groningen (Groningen, the
Netherlands), and were derived from outcrossing
SERT+/− rats.74 Animals were supplied ad libitum
with standard lab chow (RMH-B, AB Diets;
Woerden, the Netherlands) and water and were
kept on a 12:12 h light-dark cycle (lights off at
11:00 h), with an ambient temperature of 21 ± 2°C
and humidity of 50 ± 5%. Cages were cleaned weekly,
and animals were provided with a wooden stick for
gnawing (10x2x2cm) and nesting material (Enviro-
dri™, Shepherd Specialty Papers, Richland,MI, USA).
During pregnancy, females were housed individually
in type III Makrolon cages (38.2x22.0x15.0cm) and
stayed with their pups until postnatal day (PND)21.
Animals were weaned at PND21 and group housed
in same-sex cages of 3–5 animals in type IV
(55.6x33.4x19.5cm) Makrolon cages. Genotyping of
the animals was performed as described previously.6
All experimental procedures were approved by the
Institutional Animal Care and Use Committee of
The University of Groningen and were conducted
in agreement with the Law on Animal Experiments
of The Netherlands.
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Early life stress in a rat model of maternal
vulnerability
Our rat model of maternal vulnerability (MV) con-
sists of heterozygous SERT knockout (SERT+/−)
female rats. The early life stress protocol was con-
ducted as previously described.6 In short, SERT+/−
females were mated with SERT+/− males (F0).
Females were left undisturbed until delivery, which
was defined as PND0. From PND2 to PND15, pups
were either separated from the dam for 6 hours
per day – early life stress, or handled 15 minutes
per day to control for litter disturbances – control
handling (Figure 1(a)). Randomization was per-
formed by alternating assignment of stress or control
condition to litters placed in the same room. Both
groups were handled by the same experimenters.
The SERT+/− female pups from these nests (F1)
then matured to become the sMV- and cMV
females.
Breeding and fluoxetine treatment
sMV and cMV females were mated with wildtype
males. Females were between the age of 3 and
6 months, and mated when in estrus (checked
with a disinfected impedance meter, model MK-
11, Muromachi, Tokyo, Japan). This was termed
gestational day (GD)0. The males were removed
after 24 hours, and the females stayed isolated in
a type III cage. Throughout pregnancy and lacta-
tion, from GD1 until PND21, the dams were
weighed and received an oral gavage of either
a clinically relevant dose of 10 mg/kg fluoxetine
(FLX, Fluoxetine 20 PCH, Pharmachemie BV, the
Netherlands),75 or vehicle (Veh) daily at 11:00AM
(Figure 1(b)). Methylcellulose (Sigma Aldrich
Chemie BV, Zwijndrecht, the Netherlands) was
used for Veh injections since it is the constituent
of the fluoxetine capsule. FLX (5 mg/mL) and MC
(1%) solutions were prepared with autoclaved
water. The gavage volume ranged from 0.9 mL to
2.0 mL (depending on body weight). Animals were
treated orally by gently picking up the animal
without restraint, and using flexible PVC feeding
tubes (40 cm length, Vygon, Valkenswaard, the
Netherlands) in order to minimize discomfort
and stress in the animals. It should be noted that
our lab has been confronted with thus far
unexplained mortality in about one fourth of MV
females as a result of fluoxetine treatment,
a phenomenon we have described elsewhere.76
This may be the result of the SERT+/− genotype
of the MV females. In future studies, wildtype
SERT+/+ rats will have to be included in order to
establish whether this is indeed a genotype * drug
effect. None of the females included in the current
study showed any signs of toxicity as a result of
FLX. In total, 4 groups of MV females were
sampled for this study: cMV-Veh (N = 20), sMV-
Veh (N = 13), cMV-FLX (N = 34) and sMV-FLX
(N = 25). The group sizes were uneven because we
were dependent on the number of animals
included in ongoing experiments. Based on the
availability of fecal samples from all time points,
the final number of animals selected for 16S rRNA
gene sequencing for this study were 11 cMV-Veh,
8 sMV-Veh, 8 cMV-FLX and 9 sMV-FLX. Because
littermates can share microbiotas, no females from
the same litter were used within each group for the
analysis. To this end, we randomly excluded 4
animals that had a litter mate in the same group
(IDs 997, 1076, 1113, 1727), leaving us with final
sample sizes of 11 cMV-Veh, 8 sMV-Veh, 7 cMV-
FLX and 6 sMV-FLX.
Fecal sample collection
Fecal samples to be sequenced were collected at GD0
(before conception), GD7, GD14, PND2, PND7,
PND14 and PND21 (Figure 1(b)). We chose not to
collect samples closer to the day of giving birth to
avoid unnecessary stress. The samples were freshly
collected directly from the animal between 10:00AM
and 11:00AM, and precautions were taken to mini-
mize sample contamination, such as the use of gloves
and disinfection of work surfaces. The samples were
placed in clean 2.0 mL Safe-Lock Eppendorf tubes
(Nijmegen, The Netherlands), snap frozen in liquid
nitrogen, and stored at −80°C.
16S rRNA gene sequencing and analysis
Genomic DNA was isolated from fecal pellets using
the PSP® Spin Stool DNA Kit (STRATEC Molecular
GmbH, Berlin, Germany), according to the manufac-
turer’s instructions for difficult to lyse bacteria. About
100–200 mg fecal matter per sample was used for the
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DNA isolation; the remainder of the sample was
stored for metabolite measurements. A dual-index
sequencing strategy targeting the V4 region of the
16S rRNA gene was employed, using barcoded pri-
mers for the Illumina platform, as described
previously.77 Library concentration was quantified
using Qubit and an additional primer dimer clean-
up step was conducted using the AMPure XP beads
according to the manufacturer’s protocol (Beckman
Coulter, Brea, CA, USA). Sequencing was executed on
a MiSeq instrument (Illumina, San Diego, CA) using
250 base paired-end chemistry at the University of
Pennsylvania Next Generation Sequencing Core. For
quality control purposes, a sample of the Human
Microbiome Project Mock Community was included
as a positive control, and water as a negative control.
Quality filtering and chimera checking yielded
7,867,454 quality-filtered sequences with a mean ±
SD depth of 35,860 ± 2560 reads per sample. Paired-
end reads were assembled and quality filtered to
include sequences with a Q score ≥ 30.
16S rRNA gene analysis was performed as
described before,36 using mothur v. 1.39 and QIIME
version 1.9.1 (Quantitative Insights Into Microbial
Ecology).78,79 Sequences < 248 bp and > 255 bp in
length and sequences with homopolymers > 10 bp in
length were removed. Operational Taxonomic Units
(OTUs) at genus level were defined with 97%
sequence similarity using clustering method CD-
HIT. A representative sequence from every OTU con-
taining ≥ 10 sequences was selected for downstream
analyses (based on the most abundant sequence).
Chimeric sequences were removed using
ChimeraSlayer. Representative sequences were
assigned to genera using the Ribosomal Database
Project (RDP) classifier v 2.2, multiple sequence align-
ment was performed using PyNAST, and a phylogeny
was built with FastTree. The samples were rarified to
1,000 sequences per sample before calculating diver-
sity metrics. The Shannon diversity index was used to
calculate alpha diversity, and weighted UniFrac dis-
tances were used to calculate beta diversity.
For quality control purposes, water samples and
genomic DNA from abovementioned mock com-
munities were sequenced and analyzed through the
bioinformatics pipeline and the expected sequences
were compared to the obtained sequences. Taxa
identified as cyanobacteria or ‘unclassified’ at the
phylum level were removed.
Analysis of microbiome data
The samples from GD7 and GD14 were grouped as
pregnancy and the samples from PND7, PND14 and
PND21 as lactation, since we observed no significant
differences within these periods in terms of alpha
diversity and beta diversity of the microbiome
(Supplementary Figure 4). Conversely, the samples
from PND2 were left out of the analysis, since they
did not fit either category (Supplementary Figure 4).
To identify the fecal microbial OTUs that differenti-
ate between pregnancy and lactation, the machine-
based learning algorithm Random Forests was used
in R version 3.4.1 as previously described.36,80 OTU
importance was ranked by the percent increase in
prediction error of the model as a result of removal
of that particular OTU from the model. The result-
ing model, derived from cMV-Veh samples, was
then applied to OTU tables from the other groups,
to see how early life stress, FLX and their combina-
tion alter the microbial signature of pregnancy and
lactation. The R package “gplots” was used to plot
OTU relative abundances as heat maps. To predict
the metabolic capacity of the gut microbiome during
pregnancy and lactation, a computational approach
known as Phylogenetic Investigation of
Communities by Reconstruction of Unobserved
States (PICRUSt) was used.81 This algorithm uses
the 16S rRNA data to predict the total metagenomic
content, and these metagenomes are then mapped
onto functional Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways in order to predict the
full functional capacity of the microbial community,
as previously described.36 Random Forests was
applied to the dataset of predicted metabolic path-
ways to identify those that shift from pregnancy to
lactation in the cMV-Veh group. Then, the impact of
early life stress, FLX, and their combination on the
proportional representation of these predicted
microbial metabolic pathways was plotted in
a heat map.
Targeted metabolomics
To draw associations between bacterial community
composition, predicted gut microbial metabolic capa-
city, and gut metabolite output, fecal metabolites were
quantified in a subset of the same samples that were
previously used for 16S rRNA sequencing. Budgetary
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consideration prevented processing of all samples.
GD7 was chosen as a representative time point for
pregnancy, and PND7 for lactation. Fecal samples
weighing about 300 mg from 5 randomly selected
animals per treatment group were used (N = 36 in
total). However, before analysis, samples from 2 ani-
mals were excluded to avoid having litter mates in the
same group (see details above). Targeted metabolo-
mics was performed by the Microbial Culture and
Metabolomics Core as part of the PennCHOP
Microbiome Program at the University of
Pennsylvania via ultra-performance liquid chromato-
graphy (Acquity UPLC system, Waters Corporation,
Milford, MA). For detailed methods, see
Supplementary Table 1. Due to technical challenges,
wewere unable to acquiremeasurements of the amino
acid tryptophan, the precursor to serotonin.
Analysis of metabolomics data
All metabolites that were detected in at least 40% of
samples were included in the analysis. For these
metabolites, missing values were replaced by half
the minimum positive value found for that metabo-
lite, assuming that missing values were the result of
the concentration being below the detection limit.
Random Forests was applied as described above to
the metabolite concentration table from the cMV-
Veh samples in order to reveal which individual
metabolites were overrepresented during pregnancy
or during lactation. The resulting model was then
applied to the data from the treatment groups, and
heat maps were generated. For predictive analysis,
the open-access online platform MetaboAnalyst 3.0
was used for pathway analysis based on the metabo-
lomics data.82 Metabolite Set Enrichment Analysis,
a metabolomic version of Gene Set Enrichment
Analysis, was used to investigate which sets of func-
tionally related metabolites differ between preg-
nancy and lactation per treatment group.83
Additional statistical methods
Microbial alpha diversity was analyzed with
a t-test to assess the difference between pregnancy
and lactation over all groups using R core package
“stats”. Then within each period, a two-way
ANOVA was used with FLX and stress as factors.
Tukey’s Honest Significant Difference post hoc
tests were used for multiple comparisons (cMV-
Veh vs sMV-Veh, cMV-Veh vs cMV-FLX, sMV-
Veh vs sMV-FLX, cMV-FLX vs sMV-FLX).
Permutational multivariate analysis of variance
using distance matrices (PERMANOVA) was
used to analyze effects of pregnancy vs lactation
and treatment group on weighted UniFrac
distances.84 PERMANOVA p-values were based
on 999 Monte Carlo simulations. Because of the
compositional nature of the data, OTU relative
abundances were transformed before applying
a two-way ANOVA and post hoc tests were as
described above. First, zero values were replaced
by half the minimum possible value – 0.0005 or
0.05% – and then, using R package “rgr”, relative
abundances were transformed using a centered
log-ratio transformation.85 Metabolite concentra-
tions were analyzed in the same way but untrans-
formed. Since the OTUs and metabolites analyzed
in this way differed between pregnancy and lacta-
tion in the cMV-Veh group, following from the
Random Forests analysis, further statistics between
periods were not conducted. A t-test was used to
analyze the GD0 alpha diversity difference
between cMV and sMV females. Correlation ana-
lysis was done and matrices were made using
“Hmisc” and “corrplot”. The statistical significance
is indicated as follows: #p < .1, *p < .05; ** p < .01;
and *** p < .001, **** p < .0001. Data are presented
as mean ± SEM, except OTU relative abundance
which is plotted as median ± IQR.
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